ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2009
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 280 citations in OpenAlex.
- Clinicopathological characteristics of a rare group of chronic active Epstein-Barr virus disease involving the gastrointestinal tract.Journal of hematopathology · 2026Article
- Localized Stage Plasmablastic Lymphoma with Ulcerative Colitis in Long-term Remission after Chemoradiotherapy.Internal medicine (Tokyo, Japan) · 2026Article
- Article
- ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCT.Journal of blood medicine · 2026Article
- The role of Epstein-Barr virus in NK/T cell lymphoproliferative disorders: molecular mechanisms and potential therapeutic strategies.Frontiers in immunology · 2026Review
- Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines.Vaccines · 2025Review
- An exploratory study on the differential diagnostic indicators between adult systemic EBV-positive T-cell lymphoproliferative disorders and angioimmunoblastic T-cell lymphoma with multiple EBV infections.Infectious agents and cancer · 2025Article
- EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.Frontiers in immunology · 2025Review
- Case Report: From IgA nephropathy to pneumonia, periappendiceal abscess, pulmonary arterial hypertension, and basal ganglia calcification: a case of chronic active Epstein-Barr infection in a child.Frontiers in pediatrics · 2025Article
- Clinical characteristics and literature review of chronic active Epstein-Barr virus-associated enteritis.Clinical case reports · 2024Article
- A successful treatment for chronic active Epstein-Barr virus disease with Nephrotic Syndrome.CEN case reports · 2024Article
- Plasma Epstein-Barr Virus DNA load for diagnostic and prognostic assessment in intestinal Epstein-Barr Virus infection.Frontiers in cellular and infection microbiology · 2024Article
- MKAN-MMI: empowering traditional medicine-microbe interaction prediction with masked graph autoencoders and KANs.Frontiers in pharmacology · 2024Article
- Updated guidelines for chronic active Epstein-Barr virus disease.International journal of hematology · 2023Review
- Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.International journal of hematology · 2023Article
- Chronic active Epstein-Barr virus infection as the basis of neoplasm development. Transformation of chronic lymphocytic leukaemia to NK-cell lymphoma/leukaemia was observed by flow cytometry - a diagnostic report.Central-European journal of immunology · 2023Article
- CD137 deficiency because of two novel biallelicClinical & translational immunology · 2023Article
- Article
- High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia.Blood advances · 2022Article
- Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundRecently novel Epstein-Barr virus (EBV) lymphoproliferative diseases (LPDs) have been identified in non-immunocompromised hosts, both in Asia and Western countries. These include aggressive T-cell and NK-cell LPDs often subsumed under the heading of chronic active Epstein-Barr virus (CAEBV) infection and EBV-driven B-cell LPDs mainly affecting the elderly.
designTo better define the pathogenesis, classification, and treatment of these disorders, participants from Asia, The Americas, Europe, and Australia presented clinical and experimental data at an international meeting.
resultsThe term systemic EBV-positive T-cell LPD, as adopted by the WHO classification, is preferred as a pathological classification over CAEBV (the favored clinical term) for those cases that are clonal. The disease has an aggressive clinical course, but may arise in the background of CAEBV. Hydroa vacciniforme (HV) and HV-like lymphoma represent a spectrum of clonal EBV-positive T-cell LPDs, which have a more protracted clinical course; spontaneous regression may occur in adult life. Severe mosquito bite allergy is a related syndrome usually of NK cell origin. Immune senescence in the elderly is associated with both reactive and neoplastic EBV-driven LPDs, including EBV-positive diffuse large B-cell lymphomas.
conclusionThe participants proposed an international consortium to facilitate further clinical and biological studies of novel EBV-driven LPDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.